Correlation Between Inhibrx and Cue Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Cue Biopharma, you can compare the effects of market volatilities on Inhibrx and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Cue Biopharma.

Diversification Opportunities for Inhibrx and Cue Biopharma

-0.21
  Correlation Coefficient

Very good diversification

The 3 months correlation between Inhibrx and Cue is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Inhibrx i.e., Inhibrx and Cue Biopharma go up and down completely randomly.

Pair Corralation between Inhibrx and Cue Biopharma

Given the investment horizon of 90 days Inhibrx is expected to under-perform the Cue Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Inhibrx is 2.02 times less risky than Cue Biopharma. The stock trades about -0.01 of its potential returns per unit of risk. The Cue Biopharma is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  102.00  in Cue Biopharma on December 28, 2024 and sell it today you would lose (2.00) from holding Cue Biopharma or give up 1.96% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Cue Biopharma

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Cue Biopharma 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Inhibrx and Cue Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Cue Biopharma

The main advantage of trading using opposite Inhibrx and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.
The idea behind Inhibrx and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Directory
Find actively traded commodities issued by global exchanges